{"transactions":[{"id":4637370,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-10-07T22:08:44.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":4.84,"value":242000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $4.80 to $5.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":6108287,"source":{"system":"sec-edgar","filing":"0001601830-26-000120","document":"wk-form4_1791410921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1856094/000160183026000120/wk-form4_1791410921.xml","form_type":"4"}},{"id":1185,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-09-02T22:01:55.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":3.34,"value":100200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."}],"balance_after":6158287,"source":{"system":"sec-edgar","filing":"0001601830-26-000103","document":"wk-form4_1788386512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1856094/000160183026000103/wk-form4_1788386512.xml","form_type":"4"}},{"id":693930,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-08-06T21:09:25.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":3.25,"value":97500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."}],"balance_after":6188287,"source":{"system":"sec-edgar","filing":"0001856094-26-000014","document":"wk-form4_1786050562.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000185609426000014/wk-form4_1786050562.xml","form_type":"4"}},{"id":711674,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-07-09T22:04:18.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":3.9625,"value":158500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.95 to $4.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":6218287,"source":{"system":"sec-edgar","filing":"0001856094-26-000011","document":"wk-form4_1783634656.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000185609426000011/wk-form4_1783634656.xml","form_type":"4"}},{"id":730039,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-22T20:32:41.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":88424,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 17,2027 or the day prior to the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":6258287,"source":{"system":"sec-edgar","filing":"0001601830-26-000088","document":"wk-form4_1782160357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000088/wk-form4_1782160357.xml","form_type":"4"}},{"id":749154,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-04T21:04:51.000Z","date":"2026-06-02","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":3.68,"value":110400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."}],"balance_after":6169863,"source":{"system":"sec-edgar","filing":"0001856094-26-000008","document":"wk-form4_1780607089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000185609426000008/wk-form4_1780607089.xml","form_type":"4"}},{"id":788240,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-05-07T20:44:43.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":3.52,"value":105600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."}],"balance_after":6199863,"source":{"system":"sec-edgar","filing":"0001856094-26-000005","document":"wk-form4_1778186681.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000185609426000005/wk-form4_1778186681.xml","form_type":"4"}},{"id":812292,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-04-08T20:58:18.000Z","date":"2026-04-07","kind":"sale","planned":true,"acquired":false,"shares":30000,"price":3.1,"value":93000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."}],"balance_after":6229863,"source":{"system":"sec-edgar","filing":"0001856094-26-000003","document":"wk-form4_1775681895.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000185609426000003/wk-form4_1775681895.xml","form_type":"4"}},{"id":860677,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-03-04T21:38:45.000Z","date":"2026-03-03","kind":"sale","planned":true,"acquired":false,"shares":170000,"price":3.46,"value":588200.0,"ownership":{"direct":true},"balance_after":6259863,"source":{"system":"sec-edgar","filing":"0001601830-26-000045","document":"wk-form4_1772660322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000045/wk-form4_1772660322.xml","form_type":"4"}},{"id":915731,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-02-06T22:53:34.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":220000,"price":4.2,"value":924000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."}],"balance_after":6429863,"source":{"system":"sec-edgar","filing":"0001601830-26-000007","document":"wk-form4_1770418411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183026000007/wk-form4_1770418411.xml","form_type":"4"}},{"id":942975,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-01-08T22:01:40.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":220000,"price":4.36,"value":959200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."}],"balance_after":6649863,"source":{"system":"sec-edgar","filing":"0001856094-26-000002","document":"wk-form4_1767909697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000185609426000002/wk-form4_1767909697.xml","form_type":"4"}},{"id":979981,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-12-04T21:51:31.000Z","date":"2025-12-02","kind":"sale","planned":true,"acquired":false,"shares":220000,"price":4.37,"value":961400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 31, 2025."}],"balance_after":6869863,"source":{"system":"sec-edgar","filing":"0001856094-25-000006","document":"wk-form4_1764885089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000185609425000006/wk-form4_1764885089.xml","form_type":"4"}},{"id":1103473,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-23T21:23:44.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":44031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":44031,"derivative":{"exercise_price":5.11,"expiration_date":"2035-06-18","underlying":"Class A Common Stock","underlying_shares":44031},"source":{"system":"sec-edgar","filing":"0001601830-25-000112","document":"wk-form4_1750713817.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000112/wk-form4_1750713817.xml","form_type":"4"}},{"id":1103472,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-23T21:23:44.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":22016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":7089863,"source":{"system":"sec-edgar","filing":"0001601830-25-000112","document":"wk-form4_1750713817.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000112/wk-form4_1750713817.xml","form_type":"4"}},{"id":1309721,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-01-06T23:02:30.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":7067847,"source":{"system":"sec-edgar","filing":"0001601830-25-000004","document":"wk-form4_1736204544.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183025000004/wk-form4_1736204544.xml","form_type":"4"}},{"id":1364734,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-11-15T00:19:48.000Z","date":"2024-11-12","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":7.6402,"value":87457.3694,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.48 to $8.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7066113,"source":{"system":"sec-edgar","filing":"0001601830-24-000205","document":"wk-form4_1731629981.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000205/wk-form4_1731629981.xml","form_type":"4"}},{"id":1378733,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-10-31T22:01:30.000Z","date":"2024-10-29","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":6.7202,"value":76926.1294,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.67 to $6.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7077560,"source":{"system":"sec-edgar","filing":"0001601830-24-000186","document":"wk-form4_1730412083.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000186/wk-form4_1730412083.xml","form_type":"4"}},{"id":1384555,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-10-17T21:27:44.000Z","date":"2024-10-15","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":6.6678,"value":76326.3066,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.50 to $6.74. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7089007,"source":{"system":"sec-edgar","filing":"0001601830-24-000179","document":"wk-form4_1729200457.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000179/wk-form4_1729200457.xml","form_type":"4"}},{"id":1390614,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-10-04T22:30:29.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":2026,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":7100454,"source":{"system":"sec-edgar","filing":"0001601830-24-000174","document":"wk-form4_1728081022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000174/wk-form4_1728081022.xml","form_type":"4"}},{"id":1391478,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-10-03T20:58:37.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":6.2156,"value":71149.9732,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.09 to $6.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7098428,"source":{"system":"sec-edgar","filing":"0001601830-24-000166","document":"wk-form4_1727989110.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000166/wk-form4_1727989110.xml","form_type":"4"}},{"id":1402137,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-19T21:48:26.000Z","date":"2024-09-17","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":6.8431,"value":78332.9657,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.74 to $7.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7109875,"source":{"system":"sec-edgar","filing":"0001601830-24-000160","document":"wk-form4_1726782500.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000160/wk-form4_1726782500.xml","form_type":"4"}},{"id":1413506,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-09-05T21:25:19.000Z","date":"2024-09-03","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":6.2652,"value":71717.7444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $5.96 to $6.70. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7121322,"source":{"system":"sec-edgar","filing":"0001601830-24-000154","document":"wk-form4_1725571513.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000154/wk-form4_1725571513.xml","form_type":"4"}},{"id":1424983,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-08-22T22:48:22.000Z","date":"2024-08-20","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":7.1226,"value":81532.4022,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.99 to $7.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7132769,"source":{"system":"sec-edgar","filing":"0001601830-24-000129","document":"wk-form4_1724366895.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000129/wk-form4_1724366895.xml","form_type":"4"}},{"id":1437666,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-08-08T21:23:10.000Z","date":"2024-08-06","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":6.8213,"value":78083.4211,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $6.64 to $6.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7144216,"source":{"system":"sec-edgar","filing":"0001601830-24-000119","document":"wk-form4_1723152181.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000119/wk-form4_1723152181.xml","form_type":"4"}},{"id":1448559,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-07-25T22:15:26.000Z","date":"2024-07-23","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":8.4774,"value":97040.7978,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.94 to $8.68. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7155663,"source":{"system":"sec-edgar","filing":"0001601830-24-000104","document":"wk-form4_1721945720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000104/wk-form4_1721945720.xml","form_type":"4"}},{"id":1455848,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-07-11T20:51:34.000Z","date":"2024-07-09","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":7.315,"value":83734.805,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.17 to $7.435. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7167110,"source":{"system":"sec-edgar","filing":"0001601830-24-000100","document":"wk-form4_1720731088.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000100/wk-form4_1720731088.xml","form_type":"4"}},{"id":1459303,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-07-03T20:39:33.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":1441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":7178557,"source":{"system":"sec-edgar","filing":"0001601830-24-000096","document":"wk-form4_1720039166.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000096/wk-form4_1720039166.xml","form_type":"4"}},{"id":1467951,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-27T23:13:26.000Z","date":"2024-06-25","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":9.5052,"value":108806.0244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.325 to $9.82. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7177116,"source":{"system":"sec-edgar","filing":"0001601830-24-000094","document":"wk-form4_1719529999.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000094/wk-form4_1719529999.xml","form_type":"4"}},{"id":1480213,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-13T21:36:16.000Z","date":"2024-06-11","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":8.4531,"value":96762.6357,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.285 to $8.66. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7188563,"source":{"system":"sec-edgar","filing":"0001601830-24-000082","document":"wk-form4_1718314568.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000082/wk-form4_1718314568.xml","form_type":"4"}},{"id":1489437,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-05T22:12:00.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":26193,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to this option will vest and become exercisable on the earlier of June 3, 2025 or the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":26193,"derivative":{"exercise_price":8.59,"expiration_date":"2034-06-03","underlying":"Class A Common Stock","underlying_shares":26193},"source":{"system":"sec-edgar","filing":"0001601830-24-000071","document":"wk-form4_1717625511.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000071/wk-form4_1717625511.xml","form_type":"4"}},{"id":1489436,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-06-05T22:12:00.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":13097,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 3, 2025 or the day prior to the Issuer's 2025 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer."}],"balance_after":7200010,"source":{"system":"sec-edgar","filing":"0001601830-24-000071","document":"wk-form4_1717625511.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000071/wk-form4_1717625511.xml","form_type":"4"}},{"id":1497479,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-05-30T22:41:24.000Z","date":"2024-05-28","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":9.1677,"value":104942.6619,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.88 to $9.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7186913,"source":{"system":"sec-edgar","filing":"0001601830-24-000067","document":"wk-form4_1717108876.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000067/wk-form4_1717108876.xml","form_type":"4"}},{"id":1513814,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-05-16T20:35:54.000Z","date":"2024-05-14","kind":"sale","planned":true,"acquired":false,"shares":20054,"price":10.1194,"value":202934.4476,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.74 to $10.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7198360,"source":{"system":"sec-edgar","filing":"0001601830-24-000055","document":"wk-form4_1715891720.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000055/wk-form4_1715891720.xml","form_type":"4"}},{"id":1530260,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-05-02T21:41:37.000Z","date":"2024-04-30","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":7.9465,"value":90963.5855,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.81 to $8.26. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7218414,"source":{"system":"sec-edgar","filing":"0001601830-24-000046","document":"wk-form4_1714686087.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000046/wk-form4_1714686087.xml","form_type":"4"}},{"id":1539084,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-04-18T21:12:34.000Z","date":"2024-04-16","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":7.6636,"value":87725.2292,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $7.54 to $7.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."}],"balance_after":7229861,"source":{"system":"sec-edgar","filing":"0001601830-24-000037","document":"wk-form4_1713474744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000037/wk-form4_1713474744.xml","form_type":"4"}},{"id":1548636,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-04-03T21:42:37.000Z","date":"2024-04-02","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":8.8182,"value":100941.9354,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.71 to $8.98 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7241308,"source":{"system":"sec-edgar","filing":"0001601830-24-000027","document":"wk-form4_1712180546.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000027/wk-form4_1712180546.xml","form_type":"4"}},{"id":1564560,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-21T21:38:02.000Z","date":"2024-03-19","kind":"sale","planned":true,"acquired":false,"shares":20054,"price":10.792,"value":216422.768,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.55 to $11.14 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7252755,"source":{"system":"sec-edgar","filing":"0001601830-24-000024","document":"wk-form4_1711057070.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000024/wk-form4_1711057070.xml","form_type":"4"}},{"id":1588556,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-03-07T23:53:38.000Z","date":"2024-03-05","kind":"sale","planned":true,"acquired":false,"shares":20054,"price":12.0577,"value":241805.1158,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.64 to $12.45 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7272809,"source":{"system":"sec-edgar","filing":"0001601830-24-000021","document":"wk-form4_1709855609.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000021/wk-form4_1709855609.xml","form_type":"4"}},{"id":1628052,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-02-21T22:37:37.000Z","date":"2024-02-20","kind":"sale","planned":true,"acquired":false,"shares":309,"price":13.0432,"value":4030.3488,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.98 to $13.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7292863,"source":{"system":"sec-edgar","filing":"0001209191-24-003708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124003708/doc4.xml","form_type":"4"}},{"id":1628051,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-02-21T22:37:37.000Z","date":"2024-02-20","kind":"sale","planned":true,"acquired":false,"shares":19745,"price":12.3117,"value":243094.5165,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.97 to $12.96 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7293172,"source":{"system":"sec-edgar","filing":"0001209191-24-003708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124003708/doc4.xml","form_type":"4"}},{"id":1653019,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-02-08T23:54:24.000Z","date":"2024-02-06","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":9.3028,"value":106489.1516,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.92 to $9.46 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7312917,"source":{"system":"sec-edgar","filing":"0001209191-24-003000","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124003000/doc4.xml","form_type":"4"}},{"id":1670666,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-01-25T23:13:25.000Z","date":"2024-01-23","kind":"sale","planned":true,"acquired":false,"shares":20054,"price":10.5756,"value":212083.0824,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.41 to $10.78 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7324364,"source":{"system":"sec-edgar","filing":"0001209191-24-002250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124002250/doc4.xml","form_type":"4"}},{"id":1680546,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-01-11T23:50:27.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":13751,"price":13.8117,"value":189924.6867,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.50 to $14.06 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7344418,"source":{"system":"sec-edgar","filing":"0001209191-24-001484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124001484/doc4.xml","form_type":"4"}},{"id":1680545,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-01-11T23:50:27.000Z","date":"2024-01-09","kind":"sale","planned":true,"acquired":false,"shares":6303,"price":13.2124,"value":83277.7572,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.5 to $13.495 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7358169,"source":{"system":"sec-edgar","filing":"0001209191-24-001484","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919124001484/doc4.xml","form_type":"4"}},{"id":1698421,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-12-28T22:48:11.000Z","date":"2023-12-26","kind":"sale","planned":true,"acquired":false,"shares":20054,"price":10.6285,"value":213143.939,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.38 to $10.89 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7364472,"source":{"system":"sec-edgar","filing":"0001209191-23-059947","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123059947/doc4.xml","form_type":"4"}},{"id":1710629,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-12-14T23:51:24.000Z","date":"2023-12-12","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":7.3987,"value":84692.9189,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.26 to $7.51 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7384526,"source":{"system":"sec-edgar","filing":"0001209191-23-058701","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123058701/doc4.xml","form_type":"4"}},{"id":1726461,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-11-30T22:41:50.000Z","date":"2023-11-28","kind":"sale","planned":true,"acquired":false,"shares":11447,"price":6.7195,"value":76918.1165,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.35 to $7.03 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7395973,"source":{"system":"sec-edgar","filing":"0001209191-23-056998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123056998/doc4.xml","form_type":"4"}},{"id":1738642,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-11-16T23:55:29.000Z","date":"2023-11-14","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":6.3197,"value":56150.5345,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.13 to $6.485 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7407420,"source":{"system":"sec-edgar","filing":"0001209191-23-055613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123055613/doc4.xml","form_type":"4"}},{"id":1751047,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-11-02T23:02:03.000Z","date":"2023-10-31","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":5.2745,"value":46863.9325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $5.21 to $5.35 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7416305,"source":{"system":"sec-edgar","filing":"0001209191-23-054225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123054225/doc4.xml","form_type":"4"}},{"id":1757372,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-10-19T21:34:49.000Z","date":"2023-10-17","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":6.5822,"value":58482.847,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.47 to $6.70 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7425190,"source":{"system":"sec-edgar","filing":"0001209191-23-053196","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123053196/doc4.xml","form_type":"4"}},{"id":1764207,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-10-05T22:25:29.000Z","date":"2023-10-03","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":7.2907,"value":64777.8695,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.01 to $7.49 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7434075,"source":{"system":"sec-edgar","filing":"0001209191-23-052258","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123052258/doc4.xml","form_type":"4"}},{"id":1775257,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-09-21T22:35:26.000Z","date":"2023-09-19","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":8.3599,"value":74277.7115,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.20 to $8.61 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7442960,"source":{"system":"sec-edgar","filing":"0001209191-23-050318","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123050318/doc4.xml","form_type":"4"}},{"id":1785565,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-09-07T23:02:26.000Z","date":"2023-09-05","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":8.7942,"value":78136.467,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.61 to $9.15 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7451845,"source":{"system":"sec-edgar","filing":"0001209191-23-048695","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123048695/doc4.xml","form_type":"4"}},{"id":1797411,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-08-24T21:51:36.000Z","date":"2023-08-22","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":8.9118,"value":79181.343,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.70 to $9.14 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7460730,"source":{"system":"sec-edgar","filing":"0001209191-23-047239","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123047239/doc4.xml","form_type":"4"}},{"id":1810609,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-08-10T21:33:24.000Z","date":"2023-08-08","kind":"sale","planned":false,"acquired":false,"shares":3272,"price":11.7468,"value":38435.5296,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.62 to $11.93 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7469615,"source":{"system":"sec-edgar","filing":"0001209191-23-045330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123045330/doc4.xml","form_type":"4"}},{"id":1810608,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-08-10T21:33:24.000Z","date":"2023-08-08","kind":"sale","planned":false,"acquired":false,"shares":14498,"price":11.0255,"value":159847.699,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.62 to $11.60 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7472887,"source":{"system":"sec-edgar","filing":"0001209191-23-045330","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123045330/doc4.xml","form_type":"4"}},{"id":1822041,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-27T22:30:05.000Z","date":"2023-07-25","kind":"sale","planned":false,"acquired":false,"shares":18719,"price":14.6089,"value":273463.9991,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $14.16 to $15.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7487385,"source":{"system":"sec-edgar","filing":"0001209191-23-043579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123043579/doc4.xml","form_type":"4"}},{"id":1822040,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-27T22:30:05.000Z","date":"2023-06-29","kind":"gift","planned":false,"acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7506104,"source":{"system":"sec-edgar","filing":"0001209191-23-043579","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123043579/doc4.xml","form_type":"4"}},{"id":1830020,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-13T20:54:10.000Z","date":"2023-07-11","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":6.8873,"value":61193.6605,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.69 to $7.20 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7520104,"source":{"system":"sec-edgar","filing":"0001209191-23-042225","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123042225/doc4.xml","form_type":"4"}},{"id":1841807,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-29T21:57:35.000Z","date":"2023-06-27","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":7.3876,"value":65638.826,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.19 to $7.575 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7528989,"source":{"system":"sec-edgar","filing":"0001209191-23-040206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123040206/doc4.xml","form_type":"4"}},{"id":1847514,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2023-06-21T21:24:40.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":25224,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares subject to this option will vest and become exercisable on the earlier of June 16, 2024 or the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":25224,"derivative":{"exercise_price":8.92,"exercise_date":"2024-06-16","expiration_date":"2033-06-16","underlying":"Class A Common Stock","underlying_shares":25224},"source":{"system":"sec-edgar","filing":"0001209191-23-038847","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123038847/doc4.xml","form_type":"4"}},{"id":1847513,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-21T21:24:40.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":12612,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 16, 2024 or the day prior to the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service to the Issuer."}],"balance_after":7537874,"source":{"system":"sec-edgar","filing":"0001209191-23-038847","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123038847/doc4.xml","form_type":"4"}},{"id":1853851,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-15T23:30:17.000Z","date":"2023-06-13","kind":"sale","planned":false,"acquired":false,"shares":15485,"price":9.9778,"value":154506.233,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $9.59 to $10.19 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7525262,"source":{"system":"sec-edgar","filing":"0001209191-23-037584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123037584/doc4.xml","form_type":"4"}},{"id":1871650,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-06-01T21:41:52.000Z","date":"2023-05-30","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":8.7939,"value":78133.8015,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.47 to $9.57 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7540747,"source":{"system":"sec-edgar","filing":"0001209191-23-033391","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123033391/doc4.xml","form_type":"4"}},{"id":1888374,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-05-17T22:22:24.000Z","date":"2023-05-16","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":5.0918,"value":45240.643,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $4.94 to $5.43 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7549632,"source":{"system":"sec-edgar","filing":"0001209191-23-030383","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123030383/doc4.xml","form_type":"4"}},{"id":1916252,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-04-20T21:37:43.000Z","date":"2023-04-18","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":5.9347,"value":52729.8095,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $5.83 to $6.25 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7558517,"source":{"system":"sec-edgar","filing":"0001209191-23-025026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123025026/doc4.xml","form_type":"4"}},{"id":1923452,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-04-06T21:38:43.000Z","date":"2023-04-04","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":6.5269,"value":57991.5065,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $6.43 to $6.84 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7567402,"source":{"system":"sec-edgar","filing":"0001209191-23-023625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123023625/doc4.xml","form_type":"4"}},{"id":1939950,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-23T21:07:59.000Z","date":"2023-03-21","kind":"sale","planned":false,"acquired":false,"shares":8885,"price":7.3994,"value":65743.669,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.27 to $7.49 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7576287,"source":{"system":"sec-edgar","filing":"0001209191-23-020799","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123020799/doc4.xml","form_type":"4"}},{"id":1960531,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-03-09T22:36:32.000Z","date":"2023-03-07","kind":"sale","acquired":false,"shares":8885,"price":8.3274,"value":73988.949,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.10 to $8.49 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7585172,"source":{"system":"sec-edgar","filing":"0001209191-23-017619","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123017619/doc4.xml","form_type":"4"}},{"id":1995291,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-23T22:48:44.000Z","date":"2023-02-21","kind":"sale","acquired":false,"shares":8885,"price":7.733,"value":68707.705,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.66 to $7.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7594057,"source":{"system":"sec-edgar","filing":"0001209191-23-012321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123012321/doc4.xml","form_type":"4"}},{"id":2024348,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-02-09T21:53:52.000Z","date":"2023-02-07","kind":"sale","acquired":false,"shares":8885,"price":8.8084,"value":78262.634,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.59 to $9.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7602942,"source":{"system":"sec-edgar","filing":"0001209191-23-008051","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123008051/doc4.xml","form_type":"4"}},{"id":2044684,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-01-26T23:04:31.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":8885,"price":8.7077,"value":77367.9145,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.49 to $8.87 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7611827,"source":{"system":"sec-edgar","filing":"0001209191-23-005098","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123005098/doc4.xml","form_type":"4"}},{"id":2055425,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-01-12T22:46:31.000Z","date":"2023-01-10","kind":"sale","acquired":false,"shares":8885,"price":7.6852,"value":68283.002,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.50 to $7.81 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7620712,"source":{"system":"sec-edgar","filing":"0001209191-23-003180","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123003180/doc4.xml","form_type":"4"}},{"id":2061704,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-01-05T23:28:09.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":1325,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were issued in accordance with the Issuer's Outside Director Compensation Policy."}],"balance_after":7629597,"source":{"system":"sec-edgar","filing":"0001209191-23-002066","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919123002066/doc4.xml","form_type":"4"}},{"id":2074782,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-12-29T22:39:25.000Z","date":"2022-12-27","kind":"sale","acquired":false,"shares":8885,"price":7.2451,"value":64372.7135,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.13 to $7.56 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7628272,"source":{"system":"sec-edgar","filing":"0001209191-22-062940","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122062940/doc4.xml","form_type":"4"}},{"id":2084796,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-12-15T22:26:25.000Z","date":"2022-12-13","kind":"sale","acquired":false,"shares":8885,"price":8.9587,"value":79598.0495,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.78 to $9.53 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7637157,"source":{"system":"sec-edgar","filing":"0001209191-22-061487","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122061487/doc4.xml","form_type":"4"}},{"id":2099741,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-12-01T22:14:55.000Z","date":"2022-11-29","kind":"sale","acquired":false,"shares":8885,"price":8.7547,"value":77785.5095,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.41 to $8.89 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7646042,"source":{"system":"sec-edgar","filing":"0001209191-22-059213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122059213/doc4.xml","form_type":"4"}},{"id":2109939,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-11-18T22:47:45.000Z","date":"2022-11-16","kind":"sale","acquired":false,"shares":17770,"price":11.1204,"value":197609.508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.63 to $11.61 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7654927,"source":{"system":"sec-edgar","filing":"0001209191-22-057958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122057958/doc4.xml","form_type":"4"}},{"id":2141869,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-10-06T01:10:50.000Z","date":"2022-10-03","kind":"grant","acquired":true,"shares":920,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were issued in accordance with the Issuer's Outside Director Compensation Policy."}],"balance_after":7672697,"source":{"system":"sec-edgar","filing":"0001209191-22-052909","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122052909/doc4.xml","form_type":"4"}},{"id":2211332,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-07-06T21:47:14.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":1186,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were issued in accordance with the Issuer's Outside Director Compensation Policy."}],"balance_after":7671777,"source":{"system":"sec-edgar","filing":"0001209191-22-041273","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122041273/doc4.xml","form_type":"4"}},{"id":2229486,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-17T00:19:33.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":36290,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36290,"derivative":{"exercise_price":6.2,"exercise_date":"2023-06-14","expiration_date":"2032-06-14","underlying":"Class A Common Stock","underlying_shares":36290},"source":{"system":"sec-edgar","filing":"0001209191-22-037642","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122037642/doc4.xml","form_type":"4"}},{"id":2229485,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-06-17T00:19:33.000Z","date":"2022-06-14","kind":"grant","acquired":true,"shares":18145,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy.  The restricted stock units will vest on the earlier of June 14, 2023 or the day prior to the Issuer's 2023 annual meeting of stockholders."}],"balance_after":7670591,"source":{"system":"sec-edgar","filing":"0001209191-22-037642","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122037642/doc4.xml","form_type":"4"}},{"id":2303475,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-04-05T23:25:32.000Z","date":"2022-04-01","kind":"grant","acquired":true,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":7652446,"source":{"system":"sec-edgar","filing":"0001209191-22-023320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122023320/doc4.xml","form_type":"4"}},{"id":2442782,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-01-06T01:39:46.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":9625,"price":18.0289,"value":173528.1625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.00 to $18.08 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7651146,"source":{"system":"sec-edgar","filing":"0001209191-22-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122002048/doc4.xml","form_type":"4"}},{"id":2442781,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2022-01-06T01:39:46.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":7660771,"source":{"system":"sec-edgar","filing":"0001209191-22-002048","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919122002048/doc4.xml","form_type":"4"}},{"id":2459287,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-23T22:05:38.000Z","date":"2021-12-21","kind":"sale","acquired":false,"shares":9625,"price":18.751,"value":180478.375,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.21 to $19.11 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7660216,"source":{"system":"sec-edgar","filing":"0001209191-21-071103","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121071103/doc4.xml","form_type":"4"}},{"id":2478547,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-10T02:23:33.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":400,"price":21.0275,"value":8411.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $20.99 to $21.05 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7669841,"source":{"system":"sec-edgar","filing":"0001209191-21-068920","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121068920/doc4.xml","form_type":"4"}},{"id":2478546,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-10T02:23:33.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":7725,"price":20.382,"value":157450.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $19.98 to $20.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7670241,"source":{"system":"sec-edgar","filing":"0001209191-21-068920","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121068920/doc4.xml","form_type":"4"}},{"id":2478545,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-12-10T02:23:33.000Z","date":"2021-12-07","kind":"sale","acquired":false,"shares":1500,"price":19.781,"value":29671.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.98 to $19.97 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7677966,"source":{"system":"sec-edgar","filing":"0001209191-21-068920","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121068920/doc4.xml","form_type":"4"}},{"id":2500065,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-11-23T01:20:26.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":7725,"price":19.0542,"value":147193.695,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.87 to $19.44 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7679466,"source":{"system":"sec-edgar","filing":"0001209191-21-066254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121066254/doc4.xml","form_type":"4"}},{"id":2500064,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-11-23T01:20:26.000Z","date":"2021-11-18","kind":"sale","acquired":false,"shares":1900,"price":18.3218,"value":34811.42,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $17.86 to $18.835 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request."}],"balance_after":7687191,"source":{"system":"sec-edgar","filing":"0001209191-21-066254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121066254/doc4.xml","form_type":"4"}},{"id":2547965,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-10-06T00:28:15.000Z","date":"2021-10-01","kind":"grant","acquired":true,"shares":457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":7689091,"source":{"system":"sec-edgar","filing":"0001209191-21-059739","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121059739/doc4.xml","form_type":"4"}},{"id":2640472,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-07-06T21:01:13.000Z","date":"2021-07-01","kind":"grant","acquired":true,"shares":278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."}],"balance_after":7688634,"source":{"system":"sec-edgar","filing":"0001209191-21-045550","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121045550/doc4.xml","form_type":"4"}},{"id":2741565,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-22T23:50:26.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date."}],"balance_after":12500,"derivative":{"exercise_price":18,"expiration_date":"2031-04-14","underlying":"Class A Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-028026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028026/doc4.xml","form_type":"4"}},{"id":2741564,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-22T23:50:26.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2031-04-14","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-028026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028026/doc4.xml","form_type":"4"}},{"id":2741563,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2021-04-22T23:50:26.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":544743,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":544743},"source":{"system":"sec-edgar","filing":"0001209191-21-028026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028026/doc4.xml","form_type":"4"}},{"id":2741562,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-04-22T23:50:26.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":378309,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A Preferred Stock into Common Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A Preferred Stock into Common Stock had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":378309},"source":{"system":"sec-edgar","filing":"0001209191-21-028026","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028026/doc4.xml","form_type":"4"}},{"id":2741561,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-04-22T23:50:26.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":7688356,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":7688356,"source":{"system":"sec-edgar","filing":"0001209191-21-028026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028026/doc4.xml","form_type":"4"}},{"id":2741560,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T23:50:26.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":7688356,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to a reclassification exempt under Rule 16b-7, each share of Common Stock was automatically reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's IPO."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-028026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028026/doc4.xml","form_type":"4"}},{"id":2741559,"issuer":{"id":1008,"kind":"organization","name":"RECURSION PHARMACEUTICALS, INC.","symbol":"RXRX"},"owners":[{"id":1009,"kind":"person","name":"Borgeson Blake","position":1,"cik":"0001856094","reported_name":"Borgeson Blake","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T23:50:26.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":923052,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A Preferred Stock into Common Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of Series A-1 Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of Recursion Pharmaceuticals, Inc.'s (the \"Issuer\") initial public offering of Class A Common Stock (the \"IPO\"). The right to convert Series A-1 Preferred Stock into Common Stock had no expiration date."}],"balance_after":7688356,"source":{"system":"sec-edgar","filing":"0001209191-21-028026","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1601830/000120919121028026/doc4.xml","form_type":"4"}}],"next_cursor":"2021-04-22T23:50:26.000000Z,2741559"}